Core Viewpoint - The successful germination and survival rates of Salix and Caragana species in the Mu Us Desert exceed 90%, addressing a long-standing technical challenge in ecological restoration [1][3]. Group 1: Research and Development - The research team, led by Professor Sun Shiquan, initiated a project in 2021 focusing on the restoration of black and odorous water bodies using humic acid and indigenous bacteria [3]. - The team discovered that certain urban organic solid wastes, after fermentation, exhibit characteristics that enhance soil water retention, leading to the development of a nutrient-rich soil for desert improvement [3][5]. Group 2: Innovative Technology - The team developed a bamboo basket device, termed the "water core energy chip," which serves as a multifunctional platform for micro-ecosystem construction, effectively stabilizing sand and providing a conducive environment for seedling growth [5]. - This device actively absorbs limited capillary water from deeper sand layers and collects moisture from the air during specific conditions, contributing to water conservation [5]. Group 3: Future Prospects - The successful trial opens pathways for integrating urban solid waste management with desert ecological restoration, presenting a resource-circulating, environmentally friendly, and cost-effective ecological repair model [5]. - The team is in discussions with the Ordos City Construction Investment Company to further develop and apply these technologies in a 1,000-acre experimental area in the Mu Us Desert [5].

一则控股股东的减持公告，再次将科兴制药推上风口浪尖。日前，科兴制药发布公告，公司控股股东深圳科益医药控股有限公司（以下简称"科益医药"）拟 减持不超过598.92万股公司股份。 据悉，科益医药背后实控人是邓学勤，科益医药当前持有股份来源是IPO前取得。科益医药及其一致行动人上市以来未减持过科兴制药股份。 对于此次拟减持原因，科兴制药回应称，控股股东本次减持，主要出于公司股权结构相对集中的考虑，为优化公司股权结构、增加二级市场流动性。在减持 期间内，控股股东将根据市场情况、公司股价等具体情形决定是否实施本次减持股份计划，减持时间、数量、价格等存在不确定性。 不过资本市场似乎并不认可控股股东的高位减持理由。在减持公告发布后，市场评论褒贬不一。减持公告发布次日（6月5日），科兴制药股价跌幅达 8.51%，为科兴制药近一月以来较大的跌幅。 控股股东拟减持股份为IPO前取得 据公开资料，科兴制药是一家主要从事重组蛋白药物和微生态制剂的研发、生产、销售一体化的创新型生物制药企业，专注于抗病毒、肿瘤与免疫、血液、 消化、退行性疾病等治疗领域。 截至公告披露日，科益医药直接持有科兴制药1.32亿股，占总股本比例为66.01% ...

随着越来越多的新生代父母成为育儿主力军，精细化育儿趋势兴起，他们对儿童护肤消费的需求不断更迭与升级，驱动相关产业不断发展。 伴随着一大批90后、95后转换为父母身份，新生代家长的育儿观念和生活消费方式不断改变，精细化育儿成为新的趋势。他们对儿童护肤消费的需求不断更 迭与升级，驱动相关产业不断发展。 婴童护肤市场规模持续扩大。据欧睿咨询数据，预计2026年我国婴童护理市场规模将接近500亿元，其中，婴童护肤品类的市场规模预计达到180亿元。婴童 护肤从基础的清洁保湿，迈向敏感肌、湿疹、防晒、驱蚊等各个更具功效性的细分领域。 早前，这一领域多是美国强生、日本贝亲等国外老牌母婴个护品牌一直拥有较高的市场占有率。但如今不少本土美妆公司也注意到了这一细分赛道。日前， 自然堂集团旗下婴童皮肤科学功效品牌——己出，联合国家儿童医学中心复旦大学附属儿科医院皮肤科专家，在上海美博会专场沙龙活动中，发布了"复儿 爱倍健微生态平衡专利技术"，首次通过调节微生态，系统性解决婴童湿疹等常见皮肤问题反复发作的行业难题。 沙龙学术分享环节，国家儿童医学中心复旦大学附属儿科医院皮肤科专家李明教授指出：临床研究发现，皮肤微生态屏障破坏是导致干 ...

郜恒骏致辞时回顾了生物芯片上海国家工程研究中心自2001年成立以来的发展历程，感谢以烟台毓璜顶 医院宋西成教授等为代表的山东医疗界同仁在中国医药生物技术协会组织生物样本库分会耳鼻咽喉头颈 外科学组筹建(宋西成教授当选为首届组长)、山东省生物样本库联盟打造以及全国生物样本库质量和能 力认可准则培训等工作中给予的大力支持。目前，中心已在山东布局肠道微生态诊疗、治病及学科运营 三大中心，此次烟台分中心的成立是重要落地成果之一。 齐鲁晚报.齐鲁壹点孙淑玉通讯员李成修李添祎 5月11日，由烟台毓璜顶医院主办的山东省半岛微生态医学与粪菌移植论坛在烟台举行。生物芯片上海 国家工程研究中心主任、中国幽门螺杆菌分子医学中心主任郜恒骏，南京医科大学第二附属医院副院 长、微生态医学科主任张发明，烟台毓璜顶医院党委书记、院长宋西成，山东省医学会消化病学分会主 任委员、山东省立医院消化内科主任许洪伟等专家出席。论坛由烟台毓璜顶医院党委副书记刘杰主持， 来自全国的顶尖专家学者齐聚一堂，围绕肠道微生态医学前沿进展、粪菌移植技术标准化及临床应用等 核心议题展开深入研讨。 宋西成在开幕式致辞中指出，肠道微生态研究作为全球生命科学的热点领域，其 ...

近年来，吉林省长春市抢抓"双碳"机遇，用智慧和科技制造"绿色"，用理念和行动保护"生态"，如今， 这座工业城市正以崭新的姿态绘就美丽新画卷。 传统产业升级，焕发新活力 面对全球汽车产业电动化、智能化、网联化的趋势，近年来，长春积极推动传统汽车产业向新能源和智 能网联汽车转型。 走进奥迪一汽新能源汽车有限公司长春生产基地（以下简称奥迪一汽新能源），建筑楼顶和停车遮阳棚 上铺满太阳能光伏板，路灯杆上悬挂风能收集器。 作为奥迪在我国首家投产即实现碳中和的生产基地，奥迪一汽新能源在厂区内铺设了超过32万平方米的 光伏设施，预计年发电量超过3500万度。 "为保证奥迪一汽新能源项目顺利建设投产，我们在项目前、中、后期都采用驻厂式服务，会同绿色低 碳领域专家团队，开展'零碳工厂'调研帮扶，为企业输送政策、答疑解惑。"长春市生态环境局汽车经 济技术开发区分局局长张孝生说，目前全区有4家单位正在创建零碳或近零碳园区工厂。 近年来，长春大力发展生物医药、新材料、人工智能等战略性新兴产业，推动产业链向高端化、智能 化、绿色化方向发展。 建设永春生物医药城是长春市立足城市产业特色、支撑全省高质量发展的需要，作为东北生物医药产业 新 ...

Investment Rating - The report maintains a "Recommended" rating for the company, indicating a potential upside of over 15% relative to the benchmark index [6][8]. Core Views - The company experienced short-term pressure on performance, with a 10.16% year-on-year revenue growth to 1.32 billion yuan in 2024, but a 22.39% decline in net profit attributable to shareholders [3][4]. - The company is focusing on innovation and increasing R&D investment, which reached 118 million yuan in 2024, accounting for 8.95% of revenue, and is expected to drive long-term growth [5][6]. - The company has completed its capacity layout, enhancing multi-business synergy, with several projects operational by the end of 2024 [5]. Financial Performance Summary - In 2024, the company achieved revenue of 1.32 billion yuan, with a net profit of 63 million yuan, reflecting a decline in profitability due to increased competition and higher depreciation costs [3][4]. - For Q1 2025, the company reported revenue of 310 million yuan, a year-on-year increase of 8.16%, but a 24.73% decline in net profit [3][4]. - The company forecasts revenue growth rates of 10.2%, 8.4%, 8.9%, and 9.4% for the years 2024 to 2027, respectively [7][11]. Business Segment Performance - In 2024, the enzyme preparation segment generated 505 million yuan, the micro-ecology segment 193 million yuan, and the animal health products segment 308 million yuan, with respective gross margins of 63.69%, 37.29%, and 33.51% [4]. - For Q1 2025, the enzyme preparation segment achieved revenue of 120 million yuan, with a gross margin of 44.36% [4]. R&D and Innovation - The company has applied for 81 invention patents related to probiotics and has published 32 articles, enhancing its competitive strength in nutrition and health-related businesses [5][6]. - The integration of AI technology is expected to further strengthen the company's capabilities in product innovation and application design [5]. Future Earnings Forecast - The company is projected to achieve net profits of 74 million yuan in 2025, 81 million yuan in 2026, and 90 million yuan in 2027, with corresponding EPS of 0.29, 0.32, and 0.35 yuan [6][7].

本报讯 （记者刘钊）4月26日，青岛蔚蓝生物股份有限公司（以下简称"蔚蓝生物"）同时发布2024年年 度报告及2025年一季度报告。数据显示，2024年年度，公司实现营收13.21亿元，同比增长10.16%，收 入规模稳步增长，实现净利润6263.75万元。2025年一季度，公司营收达3.10亿元，同比增长8.16%。 蔚蓝生物主要从事酶制剂、微生态制剂以及动物保健品的研发、生产和销售。公司以"生物科技还原生 态世界"为宗旨，致力于为生物制造提供核心技术支持，为传统产业提供清洁节能技术，为食品安全提 供绿色解决方案，全程服务农业、食品、洗涤、健康、环保、生物催化等多个产业。公司坚持技术创新 战略，持续加大研发投入，致力于打造以技术创新和全球化驱动的工业生物平台。 2024年，公司研发投入1.18亿元，占营业收入的8.95%，同比增长6.81%，在行业中处于较高水平。公司 持续优化价值客户的服务方案与运营效率，强化主业竞争力，并在全球化布局上深化"一带一路"产业布 局，推动国际市场拓展。 据悉，酶制剂、微生态制剂等生物行业是我国战略性新兴产业，具备高效、安全、节能、环保等特点， 是我国建设资源节约型、环境友好型 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [8] Core Views - The company's probiotic business shows steady growth, with a remarkable revenue performance in Q1 2025 [8] - The company reported a slight decline in 2024 performance but anticipates accelerated revenue growth in 2025 due to strategic transformations and new customer acquisitions [8] Financial Summary - Total revenue for 2024 is projected at 303 million, with a year-on-year growth of 1.19% [8] - Net profit attributable to shareholders for 2024 is expected to be 94.36 million, reflecting a year-on-year increase of 0.94% [8] - The company forecasts a significant revenue increase in 2025, with total revenue expected to reach 434.57 million, representing a year-on-year growth of 43.52% [8] - The earnings per share (EPS) for 2024 is estimated at 0.36 yuan, with projections of 0.47 yuan for 2025 [8] - The price-to-earnings (P/E) ratio is expected to decrease from 40.27 in 2024 to 30.55 in 2025 [8] Business Performance - The probiotic business is expected to maintain a strong growth momentum, with a projected revenue increase of 26% in Q1 2025 [8] - The animal and plant micro-ecological preparation business is anticipated to see a significant growth of over 200% year-on-year in Q1 2025 due to new factory production [8] - The company is optimizing its product structure, which has positively impacted its gross margin, although the animal and plant business has slightly dragged down profitability in Q1 2025 [8]

Group 1 - The core viewpoint of the article highlights the proactive measures taken by the Hohhot New Area to create a supportive business environment, focusing on service-oriented initiatives to attract and retain enterprises [1][4][6] - Hohhot New Area aims to enhance the quality and efficiency of investment attraction by facilitating the establishment of more industrial projects by 2025 [1][7] - The area has successfully gathered 39 computing power center projects, with a total intelligent computing power scale of 51,000 P, ranking among the top in the country [4] Group 2 - Inner Mongolia Xuanji Chuangzhan Technology Co., Ltd. has established a training center that focuses on practical operations of essential subsystems for data centers, benefiting from the supportive actions of Hohhot New Area [2][3] - Inner Mongolia Baichuan Digital Technology Co., Ltd. has built production lines with an annual capacity of 130,000 units, receiving significant support from the Hohhot New Area in terms of order coordination and business development [3][4] - The Inner Mongolia Data Trading Center has seen a significant increase in business scale, with over 400 data resources listed and a transaction volume nearing 30 million yuan within six months of its establishment [3][4] Group 3 - Hohhot New Area has implemented a comprehensive support system for enterprises, including financial assistance, talent recruitment, and product promotion, which has enabled companies like Inner Mongolia Ziyin Technology Co., Ltd. to expand production capacity rapidly [5][6] - The area has initiated 43 "zero-run" service projects since 2019, significantly improving the efficiency of administrative approvals for major projects, thus reducing the time and costs for enterprises [5][6] - In the first quarter of 2025, Hohhot New Area completed project filings for 18 key industrial projects with a total investment exceeding 20 billion yuan, which will inject strong momentum into the local economy [7]